http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-082574-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc9fabad14b72d011b6fc5dad2cc03e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2011-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-082574-A1 |
| titleOfInvention | COMPOUNDS OF 1,4,5,6-TETRAHIDRO-PYRIMIDIN-2-ILAMINE, PHARMACEUTICAL COMPOSITIONS BASED ON THE COMPOUND AND PROCEDURE FOR OBTAINING THE COMPOUND |
| abstract | The compounds of the application are useful as medicaments for the treatment of diabetes, especially type 2 diabetes. Claim 1: Compounds of the formula (1) wherein R1 is selected from the group consisting of hydrogen, C1-7 alkyl , C3-7 cycloalkyl, C3-7 cycloalkyl-C1-7 alkyl and benzyl; R2 is selected from the group consisting of hydrogen, C1-7 alkyl and C3-7 cycloalkyl; R3 is selected from the group consisting of hydrogen, C1-7 alkyl and C3-7 cycloalkyl; or R2 and R3 together with the C atom to which they are attached form a C3-7 cycloalkyl ring; R4 is C1-7 alkyl or C3-7 cycloalkyl; R5 is selected from the group consisting of hydrogen, C1-7 alkyl, halogen, cyano and C1-7 alkoxy; or R4 and R5 together are - (CH2) m-, in which m is the number 2 or 3 and therefore forms a ring; R6, R7 and R8 independently of each other are chosen from hydrogen or halogen; R9 is - (CO) -R10 or -R11, in which R10 is selected from the group consisting of C1-7 alkyl, - (CHR12) m3-7 cycloalkyl, said cycloalkyl is unsubstituted or substituted by one, two or three moieties selected from the group consisting of C1-7 alkyl, hydroxy, halogen, halogen-C1-7 alkyl, cyano, benzyl and phenyl, said phenyl is unsubstituted or substituted by halogen, R12 is hydrogen or C1-7 alkyl, and m is the number 0, 1 or 2, halogen-C1-7 alkyl, hydroxy-halogen-C1-7 alkyl, C1-7 alkoxy-C1-7 alkyl, - (CHR13) n-heterocyclyl, said heterocyclyl is without replace or substituted by one, two or three moieties chosen from the group consisting of C1-7 alkyl, halogen, halogen C1-7 alkyl, hydroxy, cyano, benzyl and phenyl, said phenyl is unsubstituted or substituted by halogen, R13 is hydrogen or C1-7 alkyl, and n is the number 0, 1 or 2, and -CH (OH) -phenyl, said phenyl is unsubstituted or substituted by halogen; R11 is chosen from the group consisting of: C1-7 alkyl, - (CHR14) p3-7 cycloalkyl, said cycloalkyl is unsubstituted or substituted by one, two or three moieties chosen from the group consisting of C1-7 alkyl, hydroxy, halogen, halogen-C 1-7 alkyl, cyano, carboxyl, C 1-7 alkoxycarbonyl, carboxyC 1-7 alkyl, C 1-7 alkoxycarbonylC 1-7 alkyl, C 1-7 alkylcarbonyloxy, benzyl and phenyl, said phenyl is unsubstituted or substituted by halogen, R14 is hydrogen or C1-7 alkyl, and p is the number 0, 1 or 2, halogen-C1-7 alkyl, indanyl, which is unsubstituted or substituted by one, two or three moieties chosen from the group consisting of C1-7 alkyl, C1-7 alkoxy, carboxyl, carboxy-C1-7 alkyl and halogen, tetrahydronaphthalenyl, which is unsubstituted or substituted by one, two or three groups chosen from C1- alkyl 7 or halogen, 6,7-dihydro-5H-cyclopenta [b] pyridinyl, which is unsubstituted or substituted by one, two or three groups chosen from C1-7 alkyl or halogen or, hydroxy-halogen-C1-7 alkyl, C1-7 alkoxy-halogen-C1-7 alkyl, - (CHR15) q-heterocyclyl, said heterocyclyl is unsubstituted or substituted by one, two or three moieties chosen from the group formed C1-7 alkyl, hydroxy, halogen, halogen C1-7 alkyl, C1-7 alkoxy, halogen C1-7 alkoxy, cyano, hydroxy C1-7 alkyl, carboxyl, C1-7 alkoxycarbonyl, carboxyl alkyl C1-7, C1-7 alkoxycarbonyl C1-7 alkyl, C1-7 alkylcarbonyl, C1-7 alkylcarbonyloxy, oxo, C3-7 cycloalkyl, imidazolyl, benzyl, phenylsulfanyl and phenyl, said phenyl is unsubstituted or substituted by halogen, R15 is hydrogen or C1-7 alkyl, and q is the number 0, 1 or 2; - (CHR16) s-aryl, said aryl is unsubstituted or substituted by one, two or three moieties selected from the group consisting of C1-7 alkyl, hydroxy, halogen, halogen-C1-7 alkyl, C1-7 alkoxy, halogen -C 1-7 alkoxy, cyano, hydroxy-C 1-7 alkyl, carboxyl, C 1-7 alkoxycarbonyl, oxo, C 3-7 cycloalkyl, imidazolyl, benzyl, -SO 2 -C 1-7 alkyl, phenylsulfanyl and phenyl, said phenyl is unsubstituted or substituted by halogen, R16 is hydrogen or C1-7 alkyl, and s is the number 0, 1 or 2; and - (CHR17) t-heteroaryl, said heteroaryl is unsubstituted or substituted by one, two or three moieties selected from the group consisting of C1-7 alkyl, halogen, halogen-C1-7 alkyl, hydroxy, C1-7 alkoxy, halogen-C 1-7 alkoxy, cyano, hydroxy-C 1-7 alkyl, carboxyl, C 1-7 alkoxycarbonyl, C 1-7 alkylcarbonyl, oxo, C 3-7 cycloalkyl, imidazolyl, benzyl, phenylsulfanyl and phenyl, said phenyl is unsubstituted or substituted by halogen, R17 is hydrogen or C1-7 alkyl and t is the number 0, 1 or 2; or pharmaceutically acceptable salts thereof. |
| priorityDate | 2010-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.